29 September 2016
The United States Food and Drug Administration (FDA) hasjust approved the first artificial pancreas– the Medtronic MiniMed 670G hybrid closed-loop system – for use in people with Type 1 diabetes over the age of 14 years.
An artificial pancreas is a system that continuously monitors blood glucose levels and calculates the right amount of insulin required, before the insulin is automatically delivered via a pump.
Now that FDA have given Medtronic their approval, this particular device is likely to be available in the United States from Spring 2017.
Diabetes UK has invested heavily inartificial pancreas researchover the years, supporting clinical trials to test the technology for use at home and develop a system forpregnant women with Type 1 diabetes.
"Thank you for playing a part"
Dr Elizabeth Robertson, Director of Research at Diabetes UK, said, “Artificial pancreas technology has the potential to transform the lives of people with Type 1 diabetes, and it’s very exciting to see the first device approved for use in the United States.
“While research is still needed to develop and improve the technology further, this is a critical step towards the artificial pancreas becoming a reality for people with Type 1 diabetes across the world. This is only possible thanks to the years of work that sits behind it, and we would like to thank our many supporters for contributing to research in this area and playing a part in this fantastic achievement.”